Ductal carcinoma in situ: state of the science and roadmap to advance the field.
about
Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situBreast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNADuctal carcinoma in situ: terminology, classification, and natural historyClinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status.Gene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile.Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patientsRole of ERalpha in the differential response of Stat5a loss in susceptibility to mammary preneoplasia and DMBA-induced carcinogenesisBreast cancer in men in the United States: a population-based study of diagnosis, treatment, and survival.Establishment of clonal MIN-O transplant lines for molecular imaging via lentiviral transduction & in vitro culture.Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breastMicroenvironmental influences that drive progression from benign breast disease to invasive breast cancer.Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing.RNA-Seq of human breast ductal carcinoma in situ models reveals aldehyde dehydrogenase isoform 5A1 as a novel potential target.Identification of early molecular markers for breast cancer.Paired ductal carcinoma in situ and invasive breast cancer lesions in the D-loop of the mitochondrial genome indicate a cancerization field effect.International variation in management of screen-detected ductal carcinoma in situ of the breast.Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted?The Role of Proteomics in the Diagnosis and Treatment of Women's Cancers: Current Trends in Technology and Future OpportunitiesPredictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-Negative.Cell polarity, epithelial-mesenchymal transition, and cell-fate decision gene expression in ductal carcinoma in situ.Is there a role for postmastectomy radiation therapy in ductal carcinoma in situ?Final results from a multicenter prospective study ( JROSG 05-5) on postoperative radiotherapy for patients with ductal carcinoma in situ with an involved surgical margin or close margin widths of 1 mm or lessThe Role of High-Resolution Magic Angle Spinning 1H Nuclear Magnetic Resonance Spectroscopy for Predicting the Invasive Component in Patients with Ductal Carcinoma In Situ Diagnosed on Preoperative BiopsyDCIS and axillary nodal evaluation: compliance with national guidelines.Impact of race and ethnicity on features and outcome of ductal carcinoma in situ of the breast.Cullin-3 protein expression levels correlate with breast cancer progression.Retinoblastoma and phosphate and tensin homolog tumor suppressors: impact on ductal carcinoma in situ progressionEZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer.Microcalcifications in 1657 Patients with Pure Ductal Carcinoma in Situ of the Breast: Correlation with Clinical, Histopathologic, Biologic Features, and Local RecurrenceEarly dysregulation of cell adhesion and extracellular matrix pathways in breast cancer progressionHigh and intermediate grade ductal carcinoma in-situ of the breast: a comparison of pathologic features in core biopsies and excisions and an evaluation of core biopsy features that may predict a close or positive margin in the excision.Biology, treatment, and outcome in very young and older women with DCIS.Variation in detection of ductal carcinoma in situ during screening mammography: a survey within the International Cancer Screening Network.Ductal carcinoma in situ of the breast: morphological and molecular features implicated in progression.Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancerMolecular markers for the diagnosis and management of ductal carcinoma in situ.Local outcomes in ductal carcinoma in situ based on patient and tumor characteristics.Breast carcinoma in situ: An observational study of tumor subtype, treatment and outcomesFactors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ: A National Cancer Database Study.Ductal carcinoma in situ: treatment or active surveillance?
P2860
Q26864448-AF9BE072-D68F-41AB-9EF9-1A760E9243E8Q28259224-1C381E79-8745-4D0E-A5C4-312FF6F28226Q28296046-42566BC6-F762-483F-B56A-F0D3739C1B2FQ30436536-2815D12F-C827-425B-9FEE-BE31D06EBE20Q33794872-A4710062-6BE9-408A-AB02-1AE55407D07EQ33825677-97F16C8E-EA06-4446-BCB5-7A9A3A971651Q33884587-3743DF1D-CFB1-4844-97A6-F5400697190DQ34023239-A5A6A5D0-69DA-4F48-A6C9-57179C59C069Q34321345-2C625F8A-E5AF-4720-96BB-2ACF900122B5Q34380366-652B051E-0B51-4714-8DFE-6B2C7FC2D22FQ34444593-FC5F91C8-B3EE-4A01-B8D0-4B73EB7043A6Q34471501-AAA242A8-91A9-4E97-8366-DC24304267EDQ34510318-9843ED80-06FE-4CA3-AE02-312E136211C2Q34608080-CAF5FA21-553C-4151-9FB1-96B5C252D90FQ34627310-9272C011-33D2-4065-9608-3B057448F708Q34764889-AF74D12A-4A5A-4A77-9F0A-16F53092978AQ35112248-61FC84D6-15EA-4C5E-8E07-4B448F8159CCQ35185640-A9BFBBF1-9FF4-4C85-BA25-91DFF192A92BQ35739522-BFF6E115-BF3A-4304-816B-340E56E29D85Q35909091-C5CC85ED-29FE-4DD5-ADD1-71C58935D4CEQ36063429-5ABA2465-E055-4E0F-9F73-78322D79328CQ36078638-33B73A95-4EF2-4A16-9DC6-B8DDA52E91FAQ36113082-84EC6CF8-9ECA-4094-A20B-8770EB03FC0EQ36273345-5378D739-0119-4528-9927-480ACC17F7ACQ36287832-B49877DA-F335-49B6-87AD-727E16A05D62Q36289897-E9BC7724-BEAF-470D-BBE0-3D9DD8E2B15BQ36727409-91F2E58A-EB6D-4E3E-A052-C310C8D3D91AQ37079757-9E666F30-5CD2-405D-BFAA-D0BC958609EBQ37292550-DEFFDBC4-388C-4F96-A2F2-D02A3D90A325Q37316573-58DE51BC-7746-4728-BD1B-B57AB69990A0Q37339916-D136D25A-7286-41BB-81AF-DB35C3546B5CQ37372811-142441CC-7141-43A3-A85A-7D93F707FB69Q37417169-E6F5E013-E697-40E7-83C5-CB65D8A88CDEQ37490083-2380C9EC-0DC6-4182-9D3C-C46C69B3BAEBQ37507568-F03A85E9-4C5C-4629-B596-93DDCC62351DQ37509551-BB6E6560-CD9B-49BD-A48A-A2778D6D36AAQ37509661-22F22225-84F2-4662-89F2-A040965169A8Q37709287-703AAB2B-E388-4407-AB15-D2AE7AAA7147Q38399448-0CF29366-87FE-4131-822C-29AE882C8414Q38457619-8563E24F-04B1-4D47-81A2-F9852015E2F9
P2860
Ductal carcinoma in situ: state of the science and roadmap to advance the field.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ductal carcinoma in situ: state of the science and roadmap to advance the field.
@en
Ductal carcinoma in situ: state of the science and roadmap to advance the field.
@nl
type
label
Ductal carcinoma in situ: state of the science and roadmap to advance the field.
@en
Ductal carcinoma in situ: state of the science and roadmap to advance the field.
@nl
prefLabel
Ductal carcinoma in situ: state of the science and roadmap to advance the field.
@en
Ductal carcinoma in situ: state of the science and roadmap to advance the field.
@nl
P2093
P356
P1476
Ductal carcinoma in situ: state of the science and roadmap to advance the field.
@en
P2093
Abenaa M Brewster
Banu K Arun
Brian J Czerniecki
Constance T Albarracin
Gabriel N Hortobagyi
George H Perkins
Gildy Babiera
Henry M Kuerer
Lavinia P Middleton
Mary E Edgerton
P304
P356
10.1200/JCO.2008.18.3103
P407
P577
2008-12-08T00:00:00Z